Overview

A Phase 3 Study to Evaluate Safety and Biomarkers of Resmetirom (MGL-3196) in Patients With Non-alcoholic Fatty Liver Disease (NAFLD), MAESTRO-NAFLD-Open-Label-Extension (MAESTRO-NAFLD-OLE)

Status:
Recruiting
Trial end date:
2022-12-01
Target enrollment:
Participant gender:
Summary
A 52-Week, Multi-center, Open-label, Active Treatment Extension Study to Evaluate Safety and Tolerability of Once Daily, Oral Administration of Resmetirom (MGL-3196)
Phase:
Phase 3
Details
Lead Sponsor:
Madrigal Pharmaceuticals, Inc.